Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

翰思艾泰生物医药科技(武汉)股份有限公司

03378.HK

Clinical-stage biotech developing an oncology drug pipeline, including HX009, a bifunctional anti-PD-1 SIRP fusion protein, plus kinase inhibitors and preclinical antibody candidates (ADCs, bispecifics, mAbs) for cancer and autoimmune diseases in China and Australia.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Business changes and acquisitions
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech